Psoriasis Treatment

PSORIASIS: related articles from Derm News

• 2007.1(7) Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis
  The role of chronic inflammation causing metabolic and vascular disorders is increasingly recognized. It is hypothesized that proinflammatory cytokines contribute to atherogenesis, peripheral insulin resistance, and the development of hypertension and type II diabetes.   |   Read more ...



• 2007.1(6) The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients
  It is well established that several inflammatory-type conditions, such as arthritis, diabetes, cardiovascular disease, and irritable bowel disease exist comorbidly and at an increased incidence in patients with psoriasis. Psoriasis and other associated diseases are thought to share common inflammatory pathways.   |   Read more ...



• 2006(30) The Role of Antimalarials in the Exacerbation of Psoriasis: A Systematic Review
  MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were reviewed to identify English-language publications from 1966-2005 examining the role of antimalarials in the exacerbation of psoriasis   |   Read more ...



• 2006(25) Use of Calcipotriene Cream (Dovonex® Cream) Following Acute Treatment of Psoriasis Vulgaris with the Calcipotriene/Betamethasone Dipropionate Two-Compound Product (Taclonex®): A Randomized, Parallel-Group Clinical Trial
  A calcipotriene/betamethasone dipropionate two-compound product (Taclonex^® ointment) has been shown to be safe and effective in the treatment of psoriasis over 4 weeks. Since treatment of psoriasis is generally long-term   |   Read more ...



• 2006(19) Receptor-Selective Retinoids for Psoriasis: Focus on Tazarotene
  The first topical receptor-selective retinoid to be approved for the treatment of plaque psoriasis is tazarotene. Topical tazarotene displays an onset of action and efficacy similar to those of other established antipsoriatic agents. Common adverse events of this agent such as pruritus, burning, local skin irritation, and erythema are limited to the skin and generally mild or moderate in severity   |   Read more ...



• 2007.10(5) Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers
  Tumour necrosis factor (TNF) blockers represent an exciting advance in the management of psoriasis. However, the safety profile of these drugs is not completely established...   |   Read more ...



• 2007.11(9) PsoReg - The Swedish Registry for Systemic Psoriasis Treatment The Registry's Design and Objectives
  With the introduction of new systemic drugs for the management of psoriasis, we felt an obligation in Sweden to establish a trusted tool to monitor their use. We formed PsoReg to create a solid, long-term database in order to analyze safety and effectiveness of different systemic psoriasis treatment regimens...   |   Read more ...



• 2007.12(9) Caffeine consumption and methotrexate dosing requirement in psoriasis and psoriatic arthritis
  Recent animal and human studies have suggested that the therapeutic benefit of methotrexate in the treatment of rheumatoid arthritis may be substantially reduced in patients who are concomitantly consuming caffeine. Here, we aimed to investigate the effect of caffeine consumption on the methotrexate dosing requirements in patients with psoriasis and psoriatic arthritis.   |   Read more ...



• 2007.12(3) The Efficacy and Safety of Topically Applied Indigo Naturalis Ointment in Patients with Plaque-Type Psoriasis
  It has been reported in the Chinese literature that indigo naturalis exhibits potential antipsoriatic effects in systemic therapy. \   |   Read more ...



• 2007.12(2) Impairment of Sexual Life in Patients with Psoriasis
  Sexual life can be severely affected in patients with psoriasis. However, this component is not often assessed by clinicians. Objective: To estimate the prevalence of sexual impairment and its degree of association with clinical and personal factors among psoriasis patients...   |   Read more ...



• 2007.14(6) Complications and Adverse Reactions in the Use of Newer Biologic Agents
  New developments in genetic engineering and biotechnology have allowed the creation of bioengineered molecules that target specific steps in the pathogenesis of several immune-mediated disorders, including Crohn's disease, rheumatoid arthritis, psoriasis and psoriatic arthritis, ankylosing spondylitis, pemphigus, and B-cell lymphoma...   |   Read more ...



• 2007.14(4) Tacrolimus Ointment is Effective for Psoriasis on the Face and Intertriginous Areas in Pediatric Patients
  Children with psoriasis often have involvement of the face and intertriginous areas. While corticosteroids have been the mainstay of treatment for plaque-type psoriasis, the face and intertriginous areas are more sensitive to local effects of topical steroid use such as cutaneous atrophy....   |   Read more ...



• 2007.2(1) Treatment of psoriasis with adalimumab
  Adalimumab is an anti-tumour necrosis factor agent of use in psoriatic arthritis. The objective of this study was to assess the efficacy and safety of adalimumab in patients with plaque psoriasis unresponsive to previous therapies...   |   Read more ...



• 2007.3(8) Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis
  The aim of this study was to explore the additional effect of betamethasone dipropionate cream in the early phase of an intramuscular (IM) alefacept course, on plaque severity and on modulating T-cell subsets, cells expressing NK-receptors, epidermal proliferation and keratinocyte differentiation in lesional psoriatic skin...   |   Read more ...



• 2007.3(5) A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
  Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis...   |   Read more ...



• 2007.4(9) Severe psoriasis treated with a new macrolide: everolimus
  Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus...   |   Read more ...



• 2007.4(6) A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity
  Infliximab, an antitumour necrosis factor-a chimeric monoclonal antibody, is effective for the treatment of severe psoriasis. While the induction of antinuclear antibodies (ANA) and antidouble-stranded-DNA antibodies (anti-dsDNA-ab) is frequently observed in patients with rheumatoid arthritis and Crohn disease receiving infliximab, the incidence of induced biological and clinical autoimmunity remains unknown in the context of psoriasis...   |   Read more ...



• 2007.4(3) Psoriasis: a possible risk factor for development of coronary artery calcification
  Psoriasis: a possible risk factor for development of coronary artery calcification   |   Read more ...



• 2007.6(6) Psoriasis vulgaris and human leukocyte antigens
  Psoriasis vulgaris is a skin disease with a complex immunological and genetic Background, triggered by environmental factors. The association of human leukocyte antigens (HLA) and psoriasis has long been reported on population and familial studies...   |   Read more ...



• 2007.6(3) Acceptance of chronic illness in psoriasis vulgaris patients
  Acceptance of an illness is regarded as a considerable problem in patients with chronic diseases. Lack of acceptance can lead to lower adherence to medical treatment and delayed clinical improvement. Psoriasis, being a chronic skin disease, is known to cause considerable distress to patients...   |   Read more ...



• 2007.9(10) Interobserver reliability of the Nail Psoriasis Severity Index
  Because the Psoriasis Area and Severity Index (PASI) does not consider the severity of nail disease, a scale that assesses the extent of involvement of psoriatic nails is needed. A new grading system, the Nail Psoriasis Severity Index (NAPSI) has been proposed.   |   Read more ...



• 2007.9(9) Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute
  Psoriasis is a lifelong, incurable disease that normally develops before the age of 30 years and affects approximately 1·4% of the Spanish population. Numerous clinical trials have demonstrated the efficacy of efalizumab, a recombinant, humanized, monoclonal antibody, which has been approved for the treatment of moderate-to-severe plaque psoriasis.   |   Read more ...



• 2007.9(8) Long-term treatment of plaque psoriasis with efalizumab: an Italian experience
  Biologic agents are an important new class of drugs, offering targeted treatment for chronic skin diseases such as psoriasis. The biologic therapy efalizumab is an anti-CD11a monoclonal antibody, which was approved by the European regulatory agency in 2004 for the treatment of moderate-to-severe plaque psoriasis...   |   Read more ...



• 2007.9(7) The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital
  Efalizumab (anti-CD11a antibody) targets T cell-mediated steps important in the immunopathogenesis of psoriasis. As efalizumab is intended to be administered on a continuous long-term basis in psoriasis, it is important to share experience concerning issues commonly occurring during its use in real daily practice.   |   Read more ...



• 2007.9(6) Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark
  About 20-30% of patients with chronic plaque psoriasis have severe forms of the disease and require systemic treatment. The long-term use of conventional systemic therapies is limited by toxicity, and many patients are resistant to these treatments...   |   Read more ...



• 2007.9(5) Efalizumab in routine use: a clinical experience
  With the advent of biological therapies, continuous long-term control of psoriasis is now becoming a reality. We report our experience with biologics based on the treatment of more than 550 psoriatic patients with such compounds at our special outpatient care center of Bio-Immunotherapy at the Department of Dermatology of the Medical University of Vienna...   |   Read more ...



• 2007.9(1) Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series
  Newer biological therapies for moderate-to-severe psoriasis are being used more frequently, but unexpected effects may occur. Case presentations: We present a group of 15 patients who developed inflammatory papules while on efalizumab therapy...   |   Read more ...



• 2007.4(9) Severe psoriasis treated with a new macrolide: everolimus
  Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus...   |   Read more ...

More entries are available at the Dermatology News section